Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Glomerular Diseases
NCT05383547Unknown
- Sponsor
- Ruijin Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of bortezomib in Glomerulonephritis (GN), membranous nephropathy (MN), membranoproliferative glomerulonephritis (MPGN) and 2 more, sponsored by Ruijin Hospital. Primary endpoint: Complete Remission Rate of Proteinuria at 1 year. Status: unknown.
02
Drugs
bortezomib
03
Conditions
Glomerulonephritis (GN)membranous nephropathy (MN)membranoproliferative glomerulonephritis (MPGN)focal segmental glomerulosclerosis (FSGS)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05383547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383547.